Navigation Links
Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
Date:12/10/2007

damage, was administered on a weekly or twice weekly schedule to patients with relapsed or refractory acute leukemias. Twelve of thirty patients (40 percent) who received doses of SNS-595 of 50 mg/m2 or greater on a weekly dose schedule achieved bone marrow blast reductions to less than five percent, and four of these twelve patients achieved either complete remission (CR), complete remission without platelet recovery (CRp) or complete remission with incomplete recovery of normal hematopoietic blood elements (CRi). In the twice-weekly dosing cohort, anti-leukemic activity was observed among two out of fourteen patients (14 percent) who received doses of 40 mg/m2 or greater, including one complete remission. In both arms of the study, SNS-595's anticancer activity correlated with sustained exposure to drug above a threshold plasma concentration for at least 20 hours per week of active treatment. At the maximum-tolerated-dose, this threshold was exceeded on average in both dosing schedules.

"SNS-595 is a novel chemotherapeutic agent with a distinct mechanism of action that is demonstrating both good tolerability and early signals of promising clinical activity in a group of patients with very advanced acute leukemias," said Dr. Lancet, a principal investigator for the Phase 1 trial. "I look forward to its continued clinical development in AML, both as a single agent and in combination with other cytotoxics."

The Phase 1 clinical trial was designed to evaluate the safety and tolerability of escalating doses of SNS-595 and to establish the maximum-tolerated dose in both treatment schedules. A preliminary assessment of SNS-595's anti-tumor activity as a single agent was a secondary objective of the trial. Overall, SNS-595 was generally well tolerated, with a dose-limiting toxicity of reversible Grade 3 - 4 oral mucositis. A maximum-tolerated dose of 72 mg/m2 once-weekly and 40 mg/m2 twice-weekly was established. SNS-595 exhibited consistent and predictable
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... 26, 2014 We’ve all heard ... playing field; however, concussions in the workplace are ... with the highest risk of head injury are:, ... ,     Police officers ,     Race car ...     Delivery personnel , “Most workplace ...
(Date:7/26/2014)... According to the Banish My Bumps ... comprehensive guide that covers detailed instructions on how to ... need of any medication. , Vkool reveals in ... safe remedies for relieving symptoms of keratosis pilaris quickly. ...     How to treat children's keratosis pilaris , ...
(Date:7/26/2014)... As the category creator and ... of Xoçai is to transform and ... healthy chocolate products. One such unique element is ... berries and blueberries, an ingredient combination exclusive to ... utilized in all of Xoçai products and provides ...
(Date:7/25/2014)... July 26, 2014 Dental Perfection, a ... dental services including general dentistry, clear braces and much ... September this year in Derby. The new practice, which ... HollyBrook Medical Centre in Littleover, Derby. Patients may already ... , The new dental practice, which is headed by ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 ... China Gel Permeation Chromatography Industry” is a ... Global and China Gel Permeation Chromatography market. ... information, including Gel Permeation Chromatography definition, classification, ... as industry overview. This research covers the ...
Breaking Medicine News(10 mins):Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 2Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 3Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3
... unexplained epileptic seizure in a person over age 60 as a ... at 4,700 patients who had a seizure after age 60 and ... seizure. They compared the two groups for subsequent occurrence of stroke. ... more likely to have a stroke than those individuals who did ...
... initial mammogram immediately so any follow-up tests can be ... percent and 11 percent of all screening mammograms are ... follow-up mammogram. Many abnormal mammograms turn out to be ... cancer diagnosis within one year. Even when follow-ups and ...
... surveyed about 320 women with type 1 diabetes and ... women // had what doctors considered a “good handle” ... population, these women were three- to 12-times more likely ... blood pressure, higher birth weight babies, babies with dangerously ...
... warnings from the Food and Drug Administration may leave ... what they claim.// ,Some of the products ... Blocker, and Zone Fat Blocker.Many of these supplements claim ... consumers to lose weight without making any lifestyle changes. ...
... when arteries in the abdomen or pelvis narrow or become ... As a result, not enough oxygen-rich blood gets to the ... walk or exercise. The iliac arteries are large arteries in ... say, stent placement should be considered the standard of care ...
... all men over age 60 suffer from a non-cancerous ... lower urinary tract symptoms, and those symptoms are frequent ... stream, incomplete emptying of the bladder, etc.Based on the ... may be better than one when it comes to ...
Cached Medicine News:
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- Full Service CRO WCCT Global ... President of Business Development. Peter has been in the ... of different business development positions with some of the ... related to business development/sales management and marketing.  The experience ... him a key and strategic asset to WCCT Global ...
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
Breaking Medicine Technology:Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2Acsis Addresses Questions on the Modern Supply Chain 2
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: